ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2018年02月21日 09時00分
Source:
Eisai
エーザイ、「健康経営優良法人2018~ホワイト500~」に認定
東京, 2018年02月21日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、このたび、経済産業省が、医療団体、経済団体や自治体のリーダーから構成される日本健康会議と連携して認定制度を運営する「健康経営優良法人(大規模法人部門)2018 ~ホワイト 500~」に認定されましたのでお知らせします。
「健康経営優良法人制度」とは、地域の健康課題に即した取り組みや日本健康会議が進める健康増進の取り組みをもとに、特に優良な健康経営を実践している大企業や中小企業等の法人を顕彰する制度です。「健康経営優良法人(大規模法人部門)」の認定においては、「経営理念(経営者の自覚)」、「組織体制」、「制度・施策実行」、「評価・改善」、「法令順守・リスクマネジメント」の 5つが基準として定められています。第 2 回目となる今回は、「大規模法人部門(ホワイト 500)」として 541 法人、「中小規模法人部門」として 775 法人が認定されました。
当社は、患者様とそのご家族の喜怒哀楽を第一義に考え、そのベネフィット向上に貢献し、世界のヘルスケアの多様なニーズを充足することを企業理念と定めています。企業理念の実現のためには、会社の主要なステークホルダーズである社員の健康の維持および増進は重要な要素の一つであり、今後も健康経営の実践に向けた取り組みを推進してまいります。
本リリースの詳細は下記をご参照ください。
http://www.eisai.co.jp/news/news201814.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
MHI Thermal Systems to Launch New Model of the "Ene-Conductor" Heat Source Control System
Feb 06, 2025 16:51 JST
Hitachi establishes its fourth Corporate Venture Capital Fund to capture technology turning points and future growth opportunities
Feb 06, 2025 16:32 JST
Approval in Principle (AiP) Acquired from Classification Society for Low-Pressure Type Coastal Liquefied CO2 Carrier
Feb 05, 2025 17:46 JST
Toyota Powers On New North Carolina Automotive Battery Plant
Feb 05, 2025 13:59 JST
Toyota to Form Comprehensive Partnership on Carbon Neutrality with Shanghai and Establish a Company to Develop and Produce BEVs and Batteries
Feb 05, 2025 13:56 JST
Fujitsu to highlight AI-powered network technologies at MWC Barcelona 2025
Feb 05, 2025 10:25 JST
TOYOTA GAZOO Racing Launches Evolved GR Corolla in Japan
Feb 04, 2025 18:41 JST
Mitsubishi Heavy Industries Achieves Double-Digit Order Intake and Profit Growth in First Three Quarters, Raises Full-Year Guidance
Feb 04, 2025 18:34 JST
MAZDA TRANS AOYAMA Opens in Minami-Aoyama
Feb 04, 2025 17:38 JST
Fujitsu launches gen AI software analysis and visualization service to support optimal modernization planning
Feb 04, 2025 11:39 JST
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
Feb 03, 2025 17:23 JST
MHI Group Presents "Best Innovation 2024" Awards for Products and Activities that Contribute to Solving Social Issues
Feb 03, 2025 14:31 JST
Fujitsu and Tokai National Higher Education and Research System leverage explainable AI to enhance space weather prediction in collaboration with JAXA
Feb 03, 2025 12:05 JST
Enjoy Anime Tokyo Station in the Metaverse! ANIME TOKYO STATION ON ROBLOX Opens at 3:00 p.m. on January 31, 2025!
Feb 01, 2025 08:00 JST
DENSO Announces Third Quarter Financial Results
Jan 31, 2025 18:09 JST
Rally Driver Hiroshi Masuoka Receives the Person of Sports Merit Award in Japan
Jan 31, 2025 15:12 JST
TANAKA PRECIOUS METAL TECHNOLOGIES Launches Visi Fine(R): A Group of Precious Metal Materials for Medical Device Components
Jan 31, 2025 11:00 JST
Mazda Production and Sales Results for December 2024 and for January through December 2024
Jan 30, 2025 16:44 JST
Lexus Announces Global Sales Results for 2024
Jan 30, 2025 15:52 JST
MHI Thermal Systems Receives 2024 Agency for Natural Resources and Energy Commissioner's Award from ECCJ for TEJ35AM Electric-Driven Transport Refrigeration Unit Integrated with Isuzu's ELF EV
Jan 30, 2025 14:13 JST
More Latest Release >>
Related Release
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
2/3/2025 5:23:00 PM JST
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
1/28/2025 9:46:00 AM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
1/22/2025 5:18:00 PM JST
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
1/15/2025 10:03:00 AM JST
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
1/7/2025 9:14:00 AM JST
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
12/23/2024 5:22:00 PM JST
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
12/11/2024 2:45:00 PM JST
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
12/5/2024 11:22:00 AM JST
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
11/28/2024 4:26:00 PM JST
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
11/26/2024 3:50:00 PM JST
More Press release >>